FDA Approves Moderna's mRNA Flu Vaccine for Adults 50+
The U.S. Food and Drug Administration has approved Moderna's mFlusiva, the first flu vaccine utilizing mRNA technology similar to COVID-19 vaccines. The vaccine showed a 27% higher effectiveness rate compared to conventional flu shots in clinical trials.
Key takeaways
- The U.S. FDA has approved Moderna's mFlusiva, the first flu vaccine using mRNA technology.
- Approved for individuals aged 50 and older, mFlusiva demonstrated a 27% increase in effectiveness compared to conventional flu vaccines.
- The mRNA platform allows for faster vaccine production, potentially improving the match with circulating flu strains.
What Happened
The U.S. Food and Drug Administration has approved Moderna's mFlusiva, the nation's first influenza vaccine developed with mRNA technology. This new vaccine employs the same scientific platform as the COVID-19 vaccines produced by Moderna and Pfizer. It is now available for individuals aged 50 and older in anticipation of the upcoming flu season.
Why It Matters
Influenza causes thousands of deaths and hundreds of thousands of hospitalizations annually in the United States. Conventional flu vaccines typically range from 22% to 56% effectiveness, partly due to challenges in accurately predicting circulating flu strains months in advance. The new mRNA vaccine offers the potential for faster production, enabling a quicker response to evolving virus strains and potentially leading to improved protection.
Background
Traditional flu vaccines are often produced in chicken eggs, a process that can take an extended period. In contrast, mRNA vaccines provide the body with genetic instructions to produce viral proteins, stimulating an immune response. Clinical trials involving over 40,000 participants demonstrated that mFlusiva was approximately 27% more effective than standard flu shots and generates a stronger, longer-lasting immune response.
Key Facts
- Moderna's mFlusiva, an mRNA-based flu vaccine, has been approved by the U.S. Food and Drug Administration.
- The vaccine is indicated for individuals aged 50 and older.
- Clinical trials showed mFlusiva was 27% more effective than conventional flu shots.
- mRNA vaccines can be manufactured more rapidly than traditional vaccines, which are typically egg-based.
- Production of the mRNA flu shot takes two to three months from strain selection to rollout, compared to about six months for traditional shots.
What Happens Next
The approval requires Moderna to conduct an additional clinical trial in individuals aged 65 and older. Post-market studies are also mandated, particularly for the older age group, reflecting heightened scientific scrutiny of mRNA products.
Sources reviewed
Project Chintan independently synthesized and analyzed information cross-checked across the sources listed above.
Related stories
Measles Cases Rise in Pennsylvania Amid State Outbreak
Trump's Vaccine Plan Faces Hurdles: Experts Cite Costs and Logistics
Supreme Court Criticizes FSSAI Over Delayed Food Warning Labels
